Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Here’s Why

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped down prior to trading on Monday . The stock had previously closed at $28.90, but opened at $26.72. Chugai Pharmaceutical shares last traded at $27.48, with a volume of 26,567 shares traded.

Analyst Ratings Changes

A number of brokerages have recently issued reports on CHGCY. UBS Group raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Tuesday, January 27th. Smbc Nikko Sec. raised Chugai Pharmaceutical to a “strong-buy” rating in a report on Wednesday, February 25th. Two research analysts have rated the stock with a Strong Buy rating, According to MarketBeat.com, the company presently has an average rating of “Strong Buy”.

Chugai Pharmaceutical Trading Down 1.0%

The stock has a fifty day moving average of $29.28 and a two-hundred day moving average of $26.66. The stock has a market capitalization of $90.50 billion, a price-to-earnings ratio of 31.61 and a beta of 0.69.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its quarterly earnings results on Thursday, January 29th. The company reported $0.25 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 22.00% and a net margin of 34.47%.The firm had revenue of $2.25 billion during the quarter. Equities analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.